Competitive Technologies Inc. extended its license five more years for the Fairfield biotech’s pain-management technology amid a slower-than-expected ramp-up of global sales, authorities say.
As a result, Competitive Tech said Friday it will limit for the time being its sales and marketing focus for its Calmare pain therapy device to North, Central and South America, and Australia and New Zealand.
Competitive Tech CEO Johnnie D. Johnson said it negotiated a five-year extension with the developers of the licensed Scrambler Therapy technology incorporated into the Calmare, Italian professor Giuseppe Marineo and Delta Research & Development.
The old agreement the parties signed April 1, 2011 that was to expire March 30, 2016, now runs through March 30, 2021, officials said.
The extension gives Competitive Tech to get its sales act together, Johnson said.
The company is attempting to position its Calmare machine as an alternative means for Medicare cancer patients to manage chronic pain without opioids or other habit-forming drugs.
Currently, the U.S. Army uses the device to treat wounded soldiers.
